The efficacy of high-dose cytarabine for patients with t(8;21) AML and with normal karyotype AML.
- Author:
Hong-Yi LI
1
;
Han YUE
;
Xu-Dong WEI
;
Xing-Hu ZHU
;
Yan-Li ZHANG
;
Li-Na ZHANG
;
Yan-Yan LIU
;
Ping WANG
;
Bai-Jun FANG
;
Yu-Fu LI
;
Yong-Ping SONG
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Child; Chromosomes, Human, Pair 21; genetics; Chromosomes, Human, Pair 8; genetics; Cytarabine; administration & dosage; Female; Humans; Karyotyping; Leukemia, Myeloid, Acute; drug therapy; genetics; Male; Middle Aged; Treatment Outcome; Young Adult
- From: Chinese Journal of Hematology 2008;29(2):110-112
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the efficacy of high-dose cytarabine (HD-Ara-C) based chemotherapy for post-remission treatment in patients with t(8;21) (q22;q22) AML-M2 and those with normal karyotype AML-M2.
METHODSAML-M2 patients were grouped into with (21 cases) or without (23 cases) t(8;21) (q22;q22) karyotype groups. After achieved remission by induction therapy, all patients received four cycles of HD-Ara-C (3 mg/m2 per 12 hours by three-hour infusion day 1 to day 3) with either mitoxantrone (7 mg m(-2) d(-1)) or aclarubicin (30 mg m(-2) d(-1)) or etoposide (70 mg m(-2) d(-1)) for 3d as post-remission treatment.
RESULTSRelapse rate in the t(8;21) and the normal karyotype groups was 29% and 57% respectively (P<0.05); 3 year disease-free survival (DFS) rate was 71% and 43% respectively (P < 0.05). and 3 year over-all survival (OS) rate was 76% and 65% respectively (P >0.05).
CONCLUSIONFour cycles of high-dose cytarabine based combination chemotherapy as post-remission treatment improves long-term disease-free survival in patients with t(8;21) (q22;q22) AML-M2.
